Search

Displaying results 261 - 270 of 536 in total
  1. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Normiflo was withdrawn from the US market in March 2000.

  2. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Food and Drug Administration (FDA) on 18 March 2010.

  3. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    In the USA it is was approved in March, 2016 as Defitelio.

  4. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  5. Drug

    Elzasonan

    go.drugbank.com/drugs/DB18969
    Investigational

    Elzasonan is under investigation in clinical trial NCT00275197 (A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive

  6. Indication

    Erythema Nodosum Leprosum

    go.drugbank.com/conditions/DBCOND0036567
    Drugs: Thalidomide
    Synonyms: Immune complex reaction co-occurrent and due to multibacillary leprosy, Immune complex reaction co-occurrent and due to multibacillary leprosy (disorder)
  7. Drug

    2,5-Dimethoxy-4-ethylamphetamine

    go.drugbank.com/drugs/DB01467
    ExperimentalIllicit

    Categories: Amphetamines
  8. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    [L39105] It was subsequently approved by the FDA in March 2024.[L50622]

  9. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    FDA approved March 27, 2012.

  10. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.